The U.S. Food and Drug Administration is cautioning companies to stop selling dietary supplements that incorporate a stimulant known as DMBA, the most recent in a series of moves to clamp down on possibly unsafe weight reduction and body-building products.
In an April 24 letter to one producer, 1ViZN LLC, the office noticed that its item Velocity listed AMP as a dietary ingredient. AMP is otherwise called 1,3-Dimethylbutylamine, DMBA, 2-amino-4-methylpentane and methyl-2-pentanamine.
The FDA said it considered Velocity debased in light of the fact that there is insufficient data to give reasonable assurance that DMBA is safe.
Recently the office cautioned five companies to quit selling dietary supplements containing a stimulant known as beta-methylphenylethylamine, or BMPEA, which is often hidden in supplements containing Acacia rigidula.
The FDA actions come in the midst of pressure from lawmakers and a Harvard University scholastic, Dr. Pieter Cohen, who has been contemplating the vicinity of synthetic stimulants in supplements.
“This is extremely welcome news,” Cohen stated. “Rather than waiting until heart attacks, strokes or deaths are definitely linked to this new designer stimulant, the FDA has now made it extremely clear to manufacturers that there is no justification to sell DMBA in supplements.”
Last year Cohen published a study showing DMBA was present in 12 supplements advertised to improve athletic performance, increase weight loss and improve brain function. He also emphasized that products containing BMPEA were still on the market a year after FDA researchers discovered the stimulant in Acacia rigidula supplements.
DMBA and BMPEA are alike to 1,3-dimethylamylamine, or DMAA, which has already been banned by the FDA.
The FDA banned a stimulant called as ephedra in 2004. Since then, companies have attempted to replace it with other stimulants purported to be natural.
“On closer review these ‘natural’ stimulants have turned out to be nothing other than new, untested drugs,” Cohen stated.